Inhibitor Therapeutics Advances Itraconazole for Gorlin Syndrome, Reports 0.265 New Surgically Eligible BCCs Per Patient-Year
核心洞察
Inhibitor Therapeutics (搜索) reported descriptive Phase IIb HP2001 data showing itraconazole was associated with 0.265 new surgically eligible basal cell carcinomas per patient-year in Gorlin Syndrome (搜索) patients.
The company is seeking FDA guidance on a surgically eligible tumor endpoint and a potential 505(b)(2) marketing application, with a Type C meeting response goal date by end of September 2026.
In HP2001, 52.7% of surgically eligible baseline tumors achieved an objective response and 13.2% of patients discontinued itraconazole due to adverse events over a median of about 7 months.
Inhibitor Therapeutics (搜索), Inc. (OTCQB: INTI) has highlighted several key developments in its itraconazole program for Basal Cell Carcinoma Nevus Syndrome (搜索) (BCCNS), also known as Gorlin Syndrome (搜索), including descriptive characterizations of prospectively collected measurements from the completed Phase IIb HP2001 study and continued engagement with the U.S. Food and Drug Administration. The updates were disclosed in the Company's Quarterly Report on Form 10-Q filed August 14, 2026.
INTI is proposing surgically eligible basal cell carcinomas as the primary efficacy endpoint for the program. The endpoint focuses on tumors that have reached a size at which surgical removal would ordinarily be warranted. It was used in the randomized, placebo-controlled Tang study of vismodegib in Gorlin Syndrome (搜索), where treatment reduced both the development of new surgically eligible tumors and the number of performed patient surgeries.
HP2001 Descriptive Findings
Applying the same site-based surgical thresholds used in the Tang study to prospectively collected HP2001 lesion measurements identified 258 surgically eligible baseline tumors. A descriptive characterization of those tumors showed that 52.7% achieved an objective response, 87.2% were controlled, and the mean best reduction in longest diameter was 40.4%. HP2001 enrolled 38 patients and followed 477 target basal cell carcinomas in total.
Applying the same surgical thresholds to prospectively collected measurements of tumors arising during HP2001 identified 10 new surgically eligible tumors across seven patients during 37.77 patient-years of on-treatment exposure, corresponding to a descriptive rate of 0.265 per patient-year. For context, the separate randomized Tang study reported approximately 2 new surgically eligible tumors per patient-year with vismodegib and approximately 29 per patient-year with placebo.
The Company emphasized that these readings are descriptive characterizations of prospectively collected measurements and should not be interpreted as prospectively specified inferential tests or as head-to-head treatment-effect estimates against the separate Tang vismodegib study.
Patient-Defined Benchmarks and Tolerability
The findings align closely with outcomes identified as important by the Gorlin Syndrome (搜索) patient community. In the Gorlin Syndrome Alliance Voice of the Patient report, 70% of respondents selected preventing BCCs from developing as one of their top three desired treatment outcomes, and 94% said that a preventive treatment reducing new basal cell carcinomas by 30% without challenging side effects would represent an improvement over current options.
Against that patient-defined benchmark, the descriptive HP2001 rate of 0.265 new surgically eligible BCCs per patient-year is an encouraging finding. The numerical separation between the HP2001 rate and the rates reported in Tang is considerably greater than the 30% threshold patients identified, although the cross-trial comparison is descriptive and is not an adjusted treatment-effect estimate.
On tolerability, 13.2% of patients discontinued itraconazole because of adverse events over a median of approximately 7.0 months on treatment in HP2001. In the randomized Tang Gorlin study, 27% of patients had discontinued vismodegib because of adverse events at a mean observation time of approximately 8 months, rising to 54% at the later study cutoff. The Company noted that although these are separate studies rather than a head-to-head safety comparison, the observed itraconazole tolerability and treatment persistence align strongly with the treatment profile patients said they wanted.
Regulatory Strategy and FDA Engagement
On July 10, 2026, INTI submitted a meeting request and associated briefing package to FDA. The Company is seeking FDA guidance on the proposed surgically eligible tumor endpoint for the non-advanced Gorlin population, the use of the existing clinical evidence within a potential marketing application under Section 505(b)(2), and the path forward for the program. The briefing package specifically asks FDA to consider the HP2001 readings, whether expressed at the surgically eligible threshold or per lesion, as descriptive characterizations of prospectively collected measurements rather than inferential post-hoc tests of a treatment effect.
FDA subsequently classified the meeting as Type C, elected to provide written responses, and has stated a goal date by the end of September 2026. The Company's regulatory position is also supported by outside scientific and clinical input, including a letter submitted to FDA from Professor D. Gareth Evans, an internationally recognized expert in inherited cancer-predisposition syndromes and Gorlin Syndrome (搜索), addressing the disease biology, the independent nature of the tumors, and the clinical importance of reducing surgical burden.
Formulation and Intellectual Property
Formulation work also advanced during the period. The completed ITZ101 pilot comparative-bioavailability study showed that the Company's 75 mg formulation produced systemic exposure most comparable to TOLSURA 65 mg, with geometric mean ratios of 105.36% for AUC0-t and 102.19% for Cmax. Based on those results, the Company intends to advance an approximate 75 mg formulation.
On August 14, 2026, the Company filed a U.S. provisional patent application covering its novel oral itraconazole formulation, including its amorphous nano/microparticle composition and related pharmaceutical uses. The filing is intended to support formulation-specific and related-use intellectual-property protection extending beyond the February 2029 expiration of the licensed Johns Hopkins University patent. Itraconazole also has FDA Orphan Drug Designation for BCCNS, which may provide a separate period of U.S. regulatory exclusivity following approval for the designated indication.
Commercial Potential and Corporate Updates
The program carries meaningful commercial potential. An internal illustrative model assumes an estimated U.S. BCCNS population of approximately 11,000 patients, approximately one-third market penetration, and illustrative pricing of $4,000 to $5,000 per patient per month. Under those assumptions, approximately 3,700 treated patients would correspond to potential peak annual U.S. revenue of approximately $178 million to $222 million. The analysis is for internal strategic planning, is highly sensitive to its assumptions, and is not Company financial guidance or a revenue forecast.
Separately, on August 3, 2026, the Delaware Court of Chancery entered a default judgment in favor of the Company against the institutional investor that failed to fund a previously announced $3.0 million registered direct offering. The judgment awarded the Company $3.0 million plus attorneys' fees and applicable interest, and the Company is pursuing enforcement and collection.
Inhibitor Therapeutics (搜索) is a pharmaceutical development company focused on developing and commercializing innovative therapeutics based on FDA-approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. The Company's current primary focus is the development of itraconazole for basal cell carcinoma nevus syndrome (搜索).